Betta Pharmaceuticals Co., Ltd. was established in 2003 and is headquartered in Hangzhou, Zhejiang. It is a national high-tech enterprise, established by the experienced talent team of returnees, with research and development (R&D) of innovative drugs as its core focus, integrating R&D, manufacturing and marketing functions. On Nov. 7th , 2016, Betta Pharmaceuticals was successfully listed on the Shenzhen Stock Exchange with the stock code: 300558.SZ.
The company has more than 1,500 employees, and has established a senior executive team for innovative drug discovery and commercialization, including dozens of returnees (Ph.D.). The company has set up R&D centers in Beijing and Hangzhou.The company independently developed China's first small molecule targeted anti-cancer drug——icotinib hydrochloride (trade name: Conmana), and was approved by the National Medical Products Administration (NMPA) in June 2011. Since its market launch, more than 280,000 lung cancer patients have been treated with the product and more than 6 million medicines have been offered through Betta’s patient assistance program. The market value has reached more than 10 billion RMB. Conmana has won the Gold Prize of China Patent Award twice as well as the China Industrial Award. It has also been awarded for the National Prize for Progress in Science and Technology, as the first such award granted to the China's chemical pharmaceutical industry and to a Zhejiang enterprise.
In November 2020, Ensartinib hydrochloride capsule (trade name: Ensacove), which is an innovative drug that was jointly developed by the company and its holding subsidiary Xcovery with independent intellectual property rights, was approved by NMPA, and became the first Category 1.1 new drug manufactured domestically in China for the treatment of advanced NSCLC with ALK mutations, which has filled in the gap of similar drugs in China.
The company continues to invest in innovative drug development for cancer, diabetes and other major diseases that seriously affect human health. Betta’s R&D expenditure increased to 740 million RMB in 2020 and to 39.7% of its revenue. Currently, there are more than 30 innovative drug projects in Betta’s pipeline with 15 in clinical stages, including 4 in phase III clinical trials. The new drug application (NDA) of Ensatinib has been submitted and was granted a priority review by the NMPA. The global multi-center phase III clinical trial of Ensartinib is ongoing and it is expected to be the first lung cancer-targeting innovative drug to be marketed globally by a Chinese pharmaecutical company.
Actively responding the call from the industry, the company also set up a healthcare innovation incubator——Betta Dream Works, to help more scientists achieve their dreams of innovation and entrepreneurship.